Home › Medivation's Xtandi Easily Outperforms Casodex In Key Trial
 

Keywords :   


Medivation's Xtandi Easily Outperforms Casodex In Key Trial

2015-01-23 22:10:48| Biotech - Topix.net

Patients taking Xtandi had a median PFS of 15.7 months compared to 5.8 months in the Casodex group. I have written many articles about Medivation and why I believe their prostate cancer drug Xtandi is going to be a multi-billion dollar drug.

Tags: key trial easily outperforms

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
02.11Subtropical Storm Patty Graphics
02.11Atlantic Tropical Weather Outlook
02.11Eastern North Pacific Tropical Weather Outlook
02.11Tropical Storm Lane Graphics
02.11Subtropical Storm Patty Graphics
02.11Tropical Storm Lane Forecast Discussion Number 4
02.11Subtropical Storm Patty Wind Speed Probabilities Number 2
02.11Summary for Tropical Storm Lane (EP3/EP132024)
More »